Literature DB >> 16709933

NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.

Leticia Quintanilla-Martinez1, Stefania Pittaluga, Cornelius Miething, Margit Klier, Martina Rudelius, Theresa Davies-Hill, Natasa Anastasov, Antonio Martinez, Angelica Vivero, Justus Duyster, Elaine S Jaffe, Falko Fend, Mark Raffeld.   

Abstract

CCAAT/enhancer binding protein beta (C/EBPbeta) is one of a 6-member family of C/EBPs. These transcription factors are involved in the regulation of various aspects of cellular growth and differentiation. Although C/EBPbeta has important functions in B- and T-cell differentiation, its expression has not been well studied in lymphoid tissues. We, therefore, analyzed its expression by immunohistochemistry and Western blot in normal lymphoid tissues and in 248 well-characterized lymphomas and lymphoma cell lines. Nonneoplastic lymphoid tissues and most B-cell, T-cell, and Hodgkin lymphomas lacked detectable levels of C/EBPbeta. In contrast, most (40 of 45; 88%) cases of ALK-positive anaplastic large cell lymphoma (ALCL) strongly expressed C/EBPbeta. Western blot analysis confirmed C/EBPbeta expression in the ALK-positive ALCLs and demonstrated elevated levels of the LIP isoform, which has been associated with increased proliferation and aggressiveness in carcinomas. Transfection of Ba/F3 and 32D cells with NPM-ALK and a kinase-inhibitable modified NPM-ALK resulted in the induction of C/EBPbeta and demonstrated dependence on NPM-ALK kinase activity. In conclusion, we report the constitutive expression of C/EBPbeta in ALK-positive ALCL and show its relationship to NPM-ALK. We suggest that C/EBPbeta is likely to play an important role in the pathogenesis and unique phenotype of this lymphoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709933     DOI: 10.1182/blood-2005-10-014258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  C/EBPα, C/EBPα oncoproteins, or C/EBPβ preferentially bind NF-κB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction.

Authors:  Julia E Dooher; Ido Paz-Priel; Simone Houng; Albert S Baldwin; Alan D Friedman
Journal:  Mol Cancer Res       Date:  2011-08-03       Impact factor: 5.852

4.  Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer.

Authors:  Natasa Anastasov; Margit Klier; Ina Koch; Daniela Angermeier; Heinz Höfler; Falko Fend; Leticia Quintanilla-Martinez
Journal:  J Hematop       Date:  2008-11-19       Impact factor: 0.196

5.  Deregulation of the endogenous C/EBPβ LIP isoform predisposes to tumorigenesis.

Authors:  Valérie Bégay; Jeske J Smink; Christoph Loddenkemper; Karin Zimmermann; Cornelia Rudolph; Marina Scheller; Doris Steinemann; Ulf Leser; Brigitte Schlegelberger; Harald Stein; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2014-11-18       Impact factor: 4.599

6.  EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

Authors:  Janine Schmidt; Irina Bonzheim; Julia Steinhilber; Ivonne A Montes-Mojarro; Carlos Ortiz-Hidalgo; Wolfram Klapper; Falko Fend; Leticia Quintanilla-Martínez
Journal:  Lab Invest       Date:  2017-06-05       Impact factor: 5.662

7.  C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.

Authors:  Natasa Anastasov; Irina Bonzheim; Martina Rudelius; Margit Klier; Therese Dau; Daniela Angermeier; Justus Duyster; Stefania Pittaluga; Falko Fend; Mark Raffeld; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

8.  FISH is more sensitive than Southern analysis at identifying increased levels of cyclin D1 gene amplified in breast cancer cell lines.

Authors:  Nie Dongsong; Jian Y Zhou
Journal:  Mol Biol Rep       Date:  2009-12-05       Impact factor: 2.316

9.  Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR.

Authors:  Leticia Quintanilla-Martinez; Julia Slotta-Huspenina; Ina Koch; Margit Klier; Eric D Hsi; Laurence de Leval; Wolfram Klapper; Stefan Gesk; Reiner Siebert; Falko Fend
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.

Authors:  Rekha Pal; Martin Janz; Deborah L Galson; Margarete Gries; Shirong Li; Korinna Jöhrens; Ioannis Anagnostopoulos; Bernd Dörken; Markus Y Mapara; Lisa Borghesi; Lela Kardava; G David Roodman; Christine Milcarek; Suzanne Lentzsch
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.